← Marker Therapeutics, Inc. (MRKR) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Marker Therapeutics, Inc. (MRKR)
Pharmaceutical Preparations · market cap $21M · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-12 (est.)
Earnings
Pipeline
3
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Marker Therapeutics (MRKR) is a micro-cap clinical-stage biotech with a $22M market cap, 5 employees, and a single disclosed pipeline asset: a low-dose folate receptor alpha (FRα) vaccine in Phase 2 for breast cancer. The company carries $14.9M in cash (roughly 32 months of runway at current burn) and no meaningful revenue outside of sporadic non-recurring items. The next scheduled event is an earnings release on 2026-08-13.
The catalyst path
- 2026-11-12 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Low dose FRα vaccine | Phase 2 | Breast Cancer |
| TPIV200 | Phase 2 | Ovarian Cancer |
| High dose FRα vaccine | Phase 2 | Breast Cancer |
Price & technical context
3-month
-15.3%
6-month
-33.8%
12-month
-8.7%
52-wk range
$0.86–$2.19
vs 50-day MA
-18.8%
vs 200-day MA
-31.9%
Realized vol
81.5%
Max drawdown
-82.5%
Daily closes through 2026-10-27. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for MRKR (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.